Tirzepatide dosing looks simple on paper — a ladder from 2.5 mg to 15 mg — but the charts you'll find online rarely explain how movement up that ladder actually gets decided, why two people on the same medication can be on very different doses a year in, or how compounded dosing differs from the branded pens. This article walks through the real structure.

As with everything we publish: this is educational information, not medical advice. Your schedule comes from your prescribing provider and the label of your specific product, and it may legitimately differ from the standard ladder below.

The standard ladder (Zepbound)

Zepbound, the FDA-approved tirzepatide product for weight management, is a once-weekly injection with a stepped schedule: [1]

  • Weeks 1–4: 2.5 mg once weekly (starting dose)
  • Week 5 onward: 5 mg once weekly
  • After at least 4 weeks at a dose, the dose may be increased in 2.5 mg steps: 7.5 mg, then 10 mg, then 12.5 mg, up to a maximum of 15 mg weekly
  • Recognized maintenance doses are 5 mg, 10 mg, or 15 mg weekly

The 2.5 mg starting dose exists to acclimate your body, not to treat — the label is explicit about that. And the ladder above is a set of permissions, not a requirement: nothing obligates a climb to 15 mg. Plenty of patients are maintained at 5 or 10 mg because that's where the benefit-versus-tolerability math works for them. [1]

Why the steps exist

Like all GLP-1-class medications, tirzepatide's most common side effects are gastrointestinal, and they cluster around dose increases. Each step gives your body at least four weeks to adapt before the next one — and slower than the minimum is explicitly allowed. If a step doesn't sit well, a provider can hold you there longer or step back down. A slower climb isn't a failed titration; it's the system working as designed. [1]

Mounjaro is the same ladder for a different job

Mounjaro — the same molecule, FDA-approved for type 2 diabetes — uses the same 2.5-to-15 mg structure, but dose decisions are driven by blood-sugar response rather than weight management. [2] If a chart you've found describes Mounjaro, the numbers will look identical; the clinical logic behind moving up the ladder is what differs.

What the trials tested

In the major weight-management trial (SURMOUNT-1), participants on the highest 15 mg weekly dose alongside lifestyle changes averaged 20.9% body-weight loss over 72 weeks. [3] As always, that figure describes a trial population at a specific dose over roughly a year and a half — it is not a promise, a timeline, or a target for any individual. The useful takeaway is structural: tirzepatide's benefit builds over months, at whatever dose you and your provider land on.

Compounded tirzepatide: vials, units, and concentration

Compounded tirzepatide is usually dispensed as a vial you draw from with a syringe, not a click-set pen. Your prescribed dose is in milligrams, but a syringe measures volume — "units" — and the conversion between them depends entirely on your vial's concentration, which varies from pharmacy to pharmacy. The same "units" instruction can mean different milligram doses from different vials. Follow the instructions issued for your specific prescription, and treat any generic internet units chart — or another person's instructions — as unsafe to borrow.

And to say it plainly, as we do everywhere: compounded tirzepatide is not FDA-approved. Same molecule, but the compounded product hasn't undergone the FDA's review for safety, effectiveness, and quality. Our article on compounded vs. brand GLP-1 covers that distinction honestly and in depth.

The decisions a chart can't make

Where you start is fixed; nearly everything after that is judgment. Whether you step up at four weeks or eight. Whether nausea at 7.5 mg means holding, slowing, or stepping back. Whether 5 mg is your maintenance dose or a waypoint. Whether tirzepatide is the right molecule for you at all — or whether it's appropriate to switch, pause, or stop. Those calls belong to a licensed medical provider who knows your history and your response — never adjust your dose on your own, and if you miss a dose, contact your provider rather than doubling up or guessing.

Where care fits

A dosage chart tells you the shape of treatment; it can't tell you your dose. That's the model Cypress is built around: a licensed medical provider reviews your assessment first, and if tirzepatide is appropriate, your plan comes with dosing instructions specific to what you're prescribed — reviewed as you go, not set once and forgotten. If you want to see what that process involves, you can learn how provider-reviewed care works.